Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
+2.44 (2.53%)
After Hours: 99.06 +0.13 (0.13%)
Jan 27, 5:16PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 98.01 - 99.54
52 week 77.90 - 102.59
Open 98.48
Vol / Avg. 3.13M/2.30M
Mkt cap 267.21B
P/E 23.84
Div/yield 2.76/2.79
EPS 4.15
Shares 2.45B
Beta 0.56
Inst. own 10%
Apr 23, 2015
Q1 2015 Novartis AG Earnings Release - 3:00AM EDT - Add to calendar
Mar 4, 2015
Novartis AG at Cowen Health Care Conference Add to calendar
Mar 3, 2015
Novartis AG at Credit Suisse Global Healthcare Conference Add to calendar
Feb 27, 2015
Novartis AG Annual Shareholders Meeting - 4:00AM EST - Add to calendar
Feb 12, 2015
Novartis AG at Leerink Global Healthcare Conference Add to calendar
Jan 27, 2015
Q4 2014 Novartis AG Earnings Call
Jan 27, 2015
Q4 2014 Novartis AG Earnings Release
Jan 12, 2015
Novartis AG at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Novartis AG at JPMorgan Healthcare Conference
Dec 4, 2014
Novartis AG at Societe General Premium Review Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 23.32% 15.79%
Operating margin 20.59% 18.52%
EBITD margin - 27.97%
Return on average assets 9.91% 7.42%
Return on average equity 17.46% 12.79%
Employees 135,000 -
CDP Score - 96 B


Lichtstrasse 35
BASEL, 4056
+41-61-6969511 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools ans over-the-counter products. It has four operating segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics; and consumer health, which include over-the-counter medicines (OTC).

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Joseph S. Jimenez Chief Executive Officer, Member of the Executive Committee
Age: 54
Bio & Compensation  - Reuters
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Harry Kirsch Member of the Management Board, Chief Financial Officer
Bio & Compensation  - Reuters
Peter Kornicker Chief Compliance Officer
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 58
Bio & Compensation  - Reuters
Juergen Brokatzky-Geiger Ph.D. Head Human Resources and Member of the Executive Committee
Age: 62
Bio & Compensation  - Reuters
Michele Galen Head Communications
Bio & Compensation  - Reuters
Paul van Arkel Head of Corporate Strategy and External Affairs
Bio & Compensation  - Reuters
Erwin Vanhaecke Ph.D. Head Novartis Group Quality
Bio & Compensation  - Reuters